Boston Scientific
-
FDA to review data on stroke-prevention implants after study finds more adverse events in women
A study published in August found that women experienced more adverse events from Boston Scientific’s Watchman implant than men. The FDA said it plans to take a closer look at data for these stroke-prevention implants, but still says the benefits outweigh the risks.
-
Abbott takes on competition with FDA approval of device to prevent afib-related strokes
Abbott Laboratories received FDA approval for its Amulet device to treat people with atrial fibrillation who are at risk of ischemic stroke. The device would go head-to-head with one developed by Boston Scientific that was approved in 2015.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Devices & Diagnostics, Health Tech
Boston Scientific to acquire cardiac monitoring company Preventice for $925M
Boston Scientific will acquire remote cardiac monitoring company Preventice for $925 million in cash and up to $300 million in milestone payments. The deal is expected to close in mid-2021.
-
Startups, Devices & Diagnostics
Boston Scientific completes Millipede acquisition for $325 million
Earlier this year, the Marlborough, Massachusetts-based medical device giant invested $90 million into Millipede with the option of acquiring the rest of the company,
-
Devices & Diagnostics, BioPharma, Pharma
Novartis, Gilead, Celgene/Agios blood cancer treatments sweep Prix Galien awards
Along with Boston Scientific’s Watchman in the technology category, Novartis and Gilead’s Kite shared the biotechnology award for CAR-T therapy, while Celgene/Agios’s Idhifa won the pharmaceutical prize.
-
Boston Scientific gives deep brain stimulation a new look
Boston Scientific’s neurostimulation device Vercise is built on cochlear implant technology, allowing it to modulate impulses between multiple contacts.
-
Medtronic wins FDA nod to launch first MR-Conditional CRT pacemakers
Medtronic becomes the first in the U.S. to win FDA approval for a quadripolar cardiac resynchronization therapy pacemaker that is also safe to use under MRI if certain conditions are met.
-
New Bos Sci acquisition raises question: Will the Lotus (valve) ever blossom?
Boston Scientific may have purchased Swiss structural heart company Symetis for many reasons but one could very well be that the Lotus aortic valve is not ready for prime time.
-
Bye bye device tax may not mean jobs galore
If one were to believe the device lobby, jobs would come roaring back once the device tax is permanently repealed. The reality is more complex.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Hospitals, Devices & Diagnostics
Boston Scientific aims to localize chemotherapy drugs to tackle liver cancer
Boston Scientific is testing microspheres coated with a chemotherapy drug that can be delivered at the tumor site in the liver to provide an alternative to chemotherapy drugs with its attendant side effects and costs.
-
Hospitals, Devices & Diagnostics
Boston Scientific acquires RF ablation firm to treat chronic pain
Cosman Medical, which makes RF generators and electrodes among other things, will become part of Boston Scientific’s neuromodulation business.
-
Boston Scientific gets FDA approval for pacemakers designed to safely undergo MR scans
With the full ImageReady system, patients are approved to get full-body MRI scans, which eliminates some of the potential risks of a device malfunctioning due to the scan.
-
Boston Scientific launches AXIOS stent designed to help manage complications with pancreatitis
The AXIOS Stent and Electrocautery Enhanced Delivery System is designed to help physicians manage serious complications from pancreatitis using a minimally invasive endoscopic approach.
-
Medical device tax suspension leads Boston Scientific to continue partnership with Mayo Clinic
Thus far, the company has paid about 1 percent of its revenue ($75 million out of $7.4 billion) under the medical device tax. Due to the tax reprieve, Boston Scientific is now putting that money toward research.
-
Boston Scientific announces new app to track stent implants in those with kidney stones
Currently, implanted stents are sometimes forgotten or left in for too long – 13 out of 100 according to the company.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
